Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 9-10/2016

01.05.2016 | original article

Severe gastritis decreases success rate of Helicobacter pylori eradication

verfasst von: MD Ismail Hakki Kalkan, Ferdane Sapmaz, Sefa Güliter, MD Pınar Atasoy

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 9-10/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

In several studies, different risk factors other than antibiotic resistance have been documented with Helicobacter pylori eradication failure. We aimed in this study to investigate the relationship of gastric density of H. pylori, the occurrence/degree of gastric atrophy, and intestinal metaplasia (IM) with success rate of H. pylori eradication.

Methods

Two hundred consecutive treatment naive patients who received bismuth containing standart quadruple treatment due to H. pylori infection documented by histopathological examination of two antral or two corpal biopsies entered this retrospective study. The updated Sydney system was used to grade the activity of gastritis, density of H. pylori colonization, atrophy, and IM. Stages III and IV of operative link for gastritis assessment (OLGA) or the operative link on gastric intestinal metaplasia assessment (OLGIM) stages was considered as severe gastritis. H. pylori eradication was determined via stool H. pylori antigen test performed 4 weeks after the end of therapy.

Results

The presence of gastric atrophy and IM was significantly higher in patients with eradication failure (p = 0.001 and 0.01, respectively). Severe gastritis (OLGA III–IV and OLGIM III–IV) rates were higher in eradication failure group. A multiple linear regression analysis showed that OLGA and OLGIM stages were to be independent risk factors for eradication failure (p = 0.03 and 0.01, respectively).

Conclusion

Our results suggested that histopathologically severe gastritis may cause H. pylori eradication failure. In addition, we found that H. pylori density was not a risk factor for treatment failure in patients who receive quadruple treatment.
Literatur
1.
Zurück zum Zitat Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:3–15. CrossRefPubMed Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:3–15. CrossRefPubMed
2.
Zurück zum Zitat Brown LM. Helicobacter pylori epidemiology and routes of transmission. Epidemiol Rev. 2000;22:283–97. CrossRefPubMed Brown LM. Helicobacter pylori epidemiology and routes of transmission. Epidemiol Rev. 2000;22:283–97. CrossRefPubMed
3.
Zurück zum Zitat Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect. 2003;5:705–13. CrossRefPubMed Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect. 2003;5:705–13. CrossRefPubMed
4.
Zurück zum Zitat IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
5.
Zurück zum Zitat Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9. CrossRefPubMed Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9. CrossRefPubMed
6.
Zurück zum Zitat Sipponen P. Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and Helicobacter pylori and its sequelae. J Clin Gastroenterol. 2001;32:196–202. CrossRefPubMed Sipponen P. Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and Helicobacter pylori and its sequelae. J Clin Gastroenterol. 2001;32:196–202. CrossRefPubMed
7.
Zurück zum Zitat Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646–64. CrossRefPubMed Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646–64. CrossRefPubMed
8.
Zurück zum Zitat Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2000;62:1143–53. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2000;62:1143–53.
9.
Zurück zum Zitat Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001. CrossRefPubMed Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001. CrossRefPubMed
10.
Zurück zum Zitat Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101:1467–75. CrossRefPubMed Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101:1467–75. CrossRefPubMed
11.
Zurück zum Zitat Furuta T, Sugimoto M, Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther. 2007;26:693–703. CrossRefPubMed Furuta T, Sugimoto M, Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther. 2007;26:693–703. CrossRefPubMed
12.
Zurück zum Zitat Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008;18:1450–4. CrossRefPubMed Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008;18:1450–4. CrossRefPubMed
13.
Zurück zum Zitat Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217–24. CrossRefPubMed Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217–24. CrossRefPubMed
14.
Zurück zum Zitat Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc. 1996;44:683–8. CrossRefPubMed Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc. 1996;44:683–8. CrossRefPubMed
15.
Zurück zum Zitat Moshkowitz M, Konikoff FM, Peled Y. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut. 1995;36:845–7. CrossRefPubMedPubMedCentral Moshkowitz M, Konikoff FM, Peled Y. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut. 1995;36:845–7. CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–81. CrossRefPubMed Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–81. CrossRefPubMed
17.
Zurück zum Zitat Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43:S373–84. CrossRefPubMed Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43:S373–84. CrossRefPubMed
18.
Zurück zum Zitat Perri F, Clemente R, Festa V. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol. 1998;30:146–50. PubMed Perri F, Clemente R, Festa V. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol. 1998;30:146–50. PubMed
19.
Zurück zum Zitat Onal IK, Gokcan H, Benzer E, Bilir G, Oztas E. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. Clin Res Hepatol Gastroenterol. 2013;37:642–6. CrossRefPubMed Onal IK, Gokcan H, Benzer E, Bilir G, Oztas E. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. Clin Res Hepatol Gastroenterol. 2013;37:642–6. CrossRefPubMed
20.
Zurück zum Zitat Fiocca R, Villani L, Luinetti O, Gianatti A, Perego M, Alvisi C, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol. 1992;420:489–98. CrossRefPubMed Fiocca R, Villani L, Luinetti O, Gianatti A, Perego M, Alvisi C, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol. 1992;420:489–98. CrossRefPubMed
21.
Zurück zum Zitat Yamamura F, Yoshikawa N, Akita Y, Mitamura K, Miyasaka N. Relationship between Helicobacter pylori infection and histologic features of gastritis in biopsy specimens in gastroduodenal diseases, including evaluation of diagnosis by polymerase chain reaction assay. J Gastroenterol. 1999;34:461–66. CrossRefPubMed Yamamura F, Yoshikawa N, Akita Y, Mitamura K, Miyasaka N. Relationship between Helicobacter pylori infection and histologic features of gastritis in biopsy specimens in gastroduodenal diseases, including evaluation of diagnosis by polymerase chain reaction assay. J Gastroenterol. 1999;34:461–66. CrossRefPubMed
22.
Zurück zum Zitat Stolte M, Stadelmann O, Bethke B, Burkard G. Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol. 1995;33:89–93. PubMed Stolte M, Stadelmann O, Bethke B, Burkard G. Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol. 1995;33:89–93. PubMed
23.
Zurück zum Zitat Wagner S, Varrentrapp M, Haruma K, Lange P, Müller MJ, Schorn T, et al. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. Z Gastroenterol. 1991;29:595–8. PubMed Wagner S, Varrentrapp M, Haruma K, Lange P, Müller MJ, Schorn T, et al. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. Z Gastroenterol. 1991;29:595–8. PubMed
24.
Zurück zum Zitat Lai YC, Wang TH, Huang SH, Yang SS, Wu CH, Chen TK, et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol. 2003;9:1537–40. CrossRefPubMedPubMedCentral Lai YC, Wang TH, Huang SH, Yang SS, Wu CH, Chen TK, et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol. 2003;9:1537–40. CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of Helicobacter pylori? Turk J Gastroenterol. 2005;16(1):29–33. PubMed Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of Helicobacter pylori? Turk J Gastroenterol. 2005;16(1):29–33. PubMed
26.
Zurück zum Zitat Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7–14 days and quadriple therapy in Turkey. World J Gastroenterol. 2004;10(5):668–71. CrossRefPubMedPubMedCentral Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7–14 days and quadriple therapy in Turkey. World J Gastroenterol. 2004;10(5):668–71. CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Nadir I, Yonem O, Ozin Y, Kilic ZM, Sezgin O. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J. 2011;104(2):102–5. CrossRefPubMed Nadir I, Yonem O, Ozin Y, Kilic ZM, Sezgin O. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J. 2011;104(2):102–5. CrossRefPubMed
28.
Zurück zum Zitat Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr. 2007;119(11–12):372–8. CrossRefPubMed Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr. 2007;119(11–12):372–8. CrossRefPubMed
29.
Zurück zum Zitat Bago J, Galović A, Belosić Halle Z, Bilić A, Bevanda M, Bago P. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr. 2004;116(14):495–9. CrossRefPubMed Bago J, Galović A, Belosić Halle Z, Bilić A, Bevanda M, Bago P. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr. 2004;116(14):495–9. CrossRefPubMed
30.
Zurück zum Zitat Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. A randomized trial. Ann Intern Med. 2007;146:556–63. CrossRefPubMed Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. A randomized trial. Ann Intern Med. 2007;146:556–63. CrossRefPubMed
31.
Zurück zum Zitat Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999;13:483–7. CrossRefPubMed Kashimura H, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999;13:483–7. CrossRefPubMed
32.
33.
Zurück zum Zitat Onal IK, Sokmensuer C, Onal ED, Ersoy O, Yeniova O, Aydinli M, et al. Clinical and pathological features of nodular gastritis in adults. Turk J Med Sci. 2009;39:719–23. Onal IK, Sokmensuer C, Onal ED, Ersoy O, Yeniova O, Aydinli M, et al. Clinical and pathological features of nodular gastritis in adults. Turk J Med Sci. 2009;39:719–23.
35.
Zurück zum Zitat de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945–52. CrossRefPubMed de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945–52. CrossRefPubMed
36.
Zurück zum Zitat Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27(2):205–23. CrossRefPubMed Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27(2):205–23. CrossRefPubMed
37.
Zurück zum Zitat Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol. 2008;23(11):1666–71. CrossRefPubMed Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol. 2008;23(11):1666–71. CrossRefPubMed
38.
Zurück zum Zitat Oda Y, Miwa J, Kaise M, Matsubara Y, Hatahara T, Ohta Y. Five-year follow-up study of histological and endoscopic alterations in the gastric mucosa after Helicobacter pylori eradication. Dig Endosc. 2004;16:213–8. CrossRef Oda Y, Miwa J, Kaise M, Matsubara Y, Hatahara T, Ohta Y. Five-year follow-up study of histological and endoscopic alterations in the gastric mucosa after Helicobacter pylori eradication. Dig Endosc. 2004;16:213–8. CrossRef
39.
Zurück zum Zitat Kamada T, Haruma K, Komoto K, Mihara M, Chen X, Yoshihara M, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter. 1999;4(3):204–10. CrossRefPubMed Kamada T, Haruma K, Komoto K, Mihara M, Chen X, Yoshihara M, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter. 1999;4(3):204–10. CrossRefPubMed
Metadaten
Titel
Severe gastritis decreases success rate of Helicobacter pylori eradication
verfasst von
MD Ismail Hakki Kalkan
Ferdane Sapmaz
Sefa Güliter
MD Pınar Atasoy
Publikationsdatum
01.05.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 9-10/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0896-2